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Interferons (IFN) are warning cytokines released upon pathogen sensing. IFN control the 22 
expression of interferon-stimulated genes (ISG) which are often crucial to restrict viral 23 
infections and to establish a cellular antiviral state (1, 2). Langerin (CD207), a well-known 24 
surface receptor of Langerhans cells (LC), belongs to the C-type lectin receptor (CLR) family 25 
and constitutes a major pathogen binding receptor able to regulate both innate and adaptive 26 
immune responses (3, 4). Importantly, this CLR was reported as an antiviral receptor, notably 27 
able to bind and internalize incoming Human Immunodeficiency Virus (HIV) virions toward 28 
Birbeck granules (BG) for degradation (5, 6). However, langerin was never viewed as a 29 
contributor of interferon-mediated antiviral immune response. We now provide evidence that 30 
langerin is an ISG whose expression is upregulated upon IFN treatment in monocyte-derived 31 
and ex vivo human skin-isolated LC. 32 
Monocyte-derived dendritic cells (MoDC) express high levels of DC-SIGN (CD209) (>95%) 33 
but negligible levels of langerin (≤ 2%) while monocyte-derived Langerhans cells (MoLC) 34 
evidenced substantial langerin expression (≥ 20%) and lowered DC-SIGN levels (Fig 1a and 35 
Sup. Fig. 1a). Upon treatment of both DC subtypes for 24h with interferon-α (IFN-α), 36 
langerin expression was significantly increased (≥ 60%) in MoLC whereas it remained very 37 
low in MoDC (≤ 2%) (Fig. 1a). Noteworthy, we noticed that langerin levels were barely 38 
increased in MoDC treated with IFN-α, suggesting that optimal IFN-α-mediated control of 39 
langerin expression required a pre-conditioning transcriptional environment, like the one set 40 
during MoLC differentiation. Interestingly, among the markers screened, CD86 and CD208 41 
were also positively upregulated upon IFN treatment, although at much lower levels 42 
compared to langerin (Fig. 1a). The enhanced expression of HLA-ABC molecules was also 43 
observed upon IFN treatment of both DC subtypes, as previously reported in lymphoid cells 44 
(7). The IFN-α-mediated upregulation of langerin expression in MoLC was confirmed by 45 
immunofluorescence microscopy analyses of MoLC, treated or not with IFN-α for 24h (Fig. 46 
1b) and further validated by immunoblotting of MoLC lysates (Sup. Fig. 1b). To expand our 47 
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findings to a more relevant LC model, we isolated ex vivo human epidermal LC (eLC) from 48 
abdominoplasties which were processed as previously described (8). Cells crawling out from 49 
the epidermal layer were treated or not with IFN-α and stained with fluorescently-coupled 50 
langerin and CD1a antibodies. As shown in Fig. 1c, the pool of langerin+ expressing cells 51 
from 3 different donors was substantially increased upon IFN-α treatment. We further 52 
evidenced that only type-I IFN (IFN-α2a, IFN-α2b, IFN-β1a and IFN-β1b), but not type-II 53 
(IFN-γ), were able to upregulate langerin expression levels (Fig. 1d), reminiscent of the ISG 54 
bone marrow stromal cell antigen-2 (BST-2 also named CD317 or tetherin) expression pattern 55 
(Sup. Fig. 2). Human eLC also showed a type-I IFN-dependent increase in langerin 56 
expression (Fig. 1e). Using human PBMC or isolated primary human CD4+ T cells in parallel 57 
to autologous MoLC and MoDC, we demonstrated a broad-spectrum IFN-α-mediated 58 
increase in Retinoic acid-inducible gene I (RIG-I) mRNA levels in all cell types while 59 
significant IFN-α-mediated langerin mRNA upregulation was seemingly confined to MoLC 60 
(Fig. 1f), as also confirmed at protein level by immunoblotting (Fig. 1g). Cells pre-treated 61 
with cycloheximide (CHX), a known protein synthesis inhibitor evidenced a decrease in both 62 
langerin and RIG-I protein expression (Fig. 1h). Importantly, CHX treatment did not impede 63 
upregulation of langerin and RIG-I gene expression upon IFN-α administration, therefore 64 
demonstrating a direct involvement of IFN-α in de novo langerin expression (Fig. 1i). 65 
Interestingly, TLR agonists administered to MoLC induced a global lower TNF-α production 66 
compared to MoDC. Yet, IFN-treated MoLC (MoLC-IFN) responded efficiently to viral-67 
mimicking TLR agonists suggesting that these cells remain endowed with efficient viral 68 
sensing and subsequent antiviral response (Sup. Fig. 3). We thus compared the antiviral 69 
capacity of MoDC and MoLC, in presence or absence of IFN, upon challenge with wild-type 70 
HIV-1 (HIV) or VSV-G pseudotyped GFP-expressing lentivectors (Lv-GFP) able to bypass 71 
langerin-mediated HIV entry restriction (5, 8). As expected, MoDC were more susceptible to 72 
HIV infection than autologous MoLC while pre-treatment with type-I IFN strongly reduced 73 
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HIV infection of both DC subtypes (Fig. 1j and 1k). However, the marked antiviral effect 74 
observed in HIV-infected MoLC over HIV-infected MoDC was not evident anymore when 75 
both cell types were pre-treated with type-I IFN and challenged with Lv-GFP (Fig. 1l) as 76 
clearly indicated by a reduced fold of inhibition of infection between the cell types (Fig. 1m). 77 
Although the infection rate was seemingly higher in both cell types when exposed to Lv-GFP 78 
compared to HIV, the antiviral effect of IFN-α on Lv-GFP infection was diminished in 79 
MoLC, but not MoDC (compare Fig. 1k and 1m). This suggests the presence of a type-I IFN-80 
inducible cell surface factor on MoLC able to limit entry of incoming HIV wild-type virions, 81 
a reported function for langerin. In conclusion, our study offers a novel aspect on the 82 
regulation of expression of the CLR langerin and extends the list of ISG as potential cellular 83 
effectors able to amplify the host antiviral response.  84 
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Figure legend 126 
(a) Interferon-mediated modulation of cell surface markers in human primary monocyte-127 
derived DC (MoDC) and LC (MoLC), pre-treated or not for 24h with 103 U/ml of IFN-α2a. 128 
(b) MoLC, treated or not with IFN-α2a for 24h, were spotted on coverslips, fixed, 129 
permeabilized and stained with langerin antibodies. Nuclei were stained with DAPI. (c) 130 
Epidermal walkout cells treated or not with IFN-α2a for 24h, were analyzed for langerin 131 
expression levels upon staining and flow cytometry analysis. (d) Graph representing langerin+ 132 
MoLC untreated or treated for 24h with IFN-α2a or IFN-α2b or IFN-β1a or IFN-β1b or IFN-133 
γ (all at 103 U/ml). (e) Same experiment as above but with epidermal walkout cells treated as 134 
indicated. (f) RT-qPCR analyses of langerin and RIG-I mRNA expression in indicated cells 135 
treated or not with IFN-α2a for 8h (n=2). (g) Lysates from MoDC and MoLC treated or not 136 
with IFN-α2a for 24h were immunoblotted with langerin and RIG-I antibodies. Loading was 137 
controlled with anti-actin (n=2). MoLC pretreated or not with 10μM of cycloheximide (CHX) 138 
for 1h, were stimulated for 24h to analyze indicated protein expression levels by 139 
immunoblotting (h) or 8h to analyze indicated transcripts levels by RT-qPCR (i). MoDC or 140 
MoLC were incubated or not with 103 U/ml IFN-α2a for 24h prior to challenge with HIV-1-141 
R5 viruses or Lv-GFP for 72h. Cells were analysed for HIV-Gag (j) or GFP (l) expression by 142 
flow cytometry and represented in a graph in which means of HIV-Gag+ cells and GFP+ cells 143 
are represented by a dotted horizontal segment (n=3). The fold of inhibition of HIV infection 144 
(k) or Lv-GFP transduction (m) were represented in graphs with data normalized to each 145 
untreated cell type (n=3). 146 




